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Puideline-Based Standardized Care Is
ssociated With Substantially Lower Mortality in
edicare Patients With Acute Myocardial Infarction
he American College of Cardiology’s
uidelines Applied in Practice (GAP) Projects in Michigan
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aryland; and Durham, North Carolina
OBJECTIVES We sought to assess the impact of the American College of Cardiology’s Guidelines Applied in
Practice (GAP) project for acute myocardial infarction (AMI) care, encompassing 33 acute-care
hospitals in southeastern Michigan, on rates of mortality in Medicare patients treated in
Michigan.
BACKGROUND The GAP project increases the use of evidence-based therapies in patients with AMI. It is
unknown whether GAP also can reduce the rate of mortality in patients with AMI.
METHODS Using a before (n  1,368) and after GAP implementation (n  1,489) cohort study, 2,857
Medicare patients with AMI were studied to assess the influence of the GAP program on
mortality. Multivariate models tested the independent impact of GAP after controlling for
other conditions on in-hospital, 30-day, and one-year mortality.
RESULTS Average patient age was 76 years, 48% were women, and 16% represented non-white
minorities. The rate of mortality decreased after GAP for each interval studied: hospital,
10.4% versus 13.6%; 30-day, 16.7% versus 21.6%; and one-year, 33.2% versus 38.3%; all p 
0.02. After multivariate adjustment, GAP correlated with a 21% to 26% reduction in
mortality, particularly at 30 days (odds ratio of GAP to baseline 0.74; 95% confidence interval
[CI] 0.59 to 0.94; p 0.012) and one year (odds ratio 0.78; 95% CI 0.64 to 0.95; p 0.013),
particularly in the patients for whom a standard discharge tool was used (1-year mortality,
odds ratio 0.53; 95% CI 0.36 to 0.76; p  0.0006).
CONCLUSIONS Embedding AMI guidelines into practice was associated with improved 30-day and one-year
mortality. This benefit is most marked when patients are cared for using standardized,
evidence-based clinical care tools. (J Am Coll Cardiol 2005;46:1242–8) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.083American College of Cardiology Foundation
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elthough the knowledge base for the management of acute
yocardial infarction (AMI) has grown substantially in
ecent decades, numerous studies have suggested that ther-
pies known to be effective are omitted in a surprising
ercentage of patients (1–5). The opportunity to improve
MI care is particularly large for our nation’s elderly, in
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October 4, 2005:1242–8 ACC’s GAP Projects in Michiganetroit Area Health Council, initiated a pilot program in
ichigan in 1999 to test the hypothesis that by embedding
he key priorities of the national guidelines into AMI care
tself, quality could be improved (9,10). Three AMI Guide-
ines Applied in Practice (GAP) projects, involving 33
ospitals, have suggested that rapid-cycle quality improve-
ent could be achieved (11). Improvement in key indicators
as optimized when caregivers adopted a systems approach,
riven by routine use of standard, admission orders, a
tandard discharge contract, and with strong physician,
urse, and administrative leadership (12). Although the
AP projects have shown improvement in key quality
ndicators, a favorable impact on patient outcomes is the real
oal of GAP. In this study, we examined the impact of
uideline-based-standard AMI care on in-hospital, 30-day,
nd one-year mortality in the Medicare beneficiaries who
articipated in the three Michigan GAP AMI projects.
ETHODS
he GAP projects. After their initial development at the
niversity of Michigan Health System (13), the ACC AMI
GAP) projects included a 10-hospital study in Southeast
ichigan in 1999 (10), a 5-hospital project in Flint and
aginaw in 2001 (11), and an 18-hospital project in South-
ast Michigan in 2002 (14). Each project built upon lessons
earned previously. A rapid-cycle quality improvement
odel was created, emphasizing a collaborative culture of
earning, sharing, and problem-solving among hospitals and
y designing care processes to assure clinical tool use (11).
he GAP project fosters systems-based care from admis-
ion to discharge, incorporating evidence-based tools into
ractice and targeting patients, physicians, and nurses. The
ethods used in the ACC GAP projects have been described
reviously (9–12,15). The clinical care tool templates, includ-
ng standardized orders, a pocket guideline, and a standardized
ischarge tool, are available elsewhere (16).
he Medicare sample. We examined the impact of GAP
n Medicare beneficiaries by studying patients treated in
ach hospital before and after the implementation of GAP.
aseline samples were created using a 50% random sample
ith at least 20 cases per hospital of Medicare AMI patients
principal diagnosis code: 410.xx) from patients treated in
he year preceding GAP implementation. The post-GAP
ample included a 95% to 100% sampling of all Medicare
MI patients in the four months immediately after GAP
mplementation at each hospital. Hospital records for each
Abbreviations and Acronyms
ACC  American College of Cardiology
AMI  acute myocardial infarction
BCBSM  Blue Cross Blue Shield of Michigan
CMS  Centers for Medicare and Medicaid Services
GAP  Guidelines Applied in Practiceatient were copied and forwarded to DynKePRO’s Centers vor Medicare & Medicaid Services (CMS) Clinical Data
bstraction Center. Each record was screened to ensure
hat AMI was the principal diagnosis. Then, data regarding
atient history, presenting symptoms and signs, rates of
omorbidity, diagnostic studies, therapies, outcomes, and
se of standard orders and/or the discharge tool were
xtracted. For quality of care indicators, only ideal cases
ere included in the denominator. Patients with contrain-
ications were excluded. To assure quality, data were
e-abstracted for a random sample of baseline and post-
AP records by the CMS Clinical Data Abstraction
enter. Reliability (94%) and accuracy (97%) were high. To
ssess for 30-day and one-year mortality, Medicare claims
ere screened using each patient’s unique identifier.
tatistical methods. We compared patients treated before
baseline) and immediately after the implementation of
AP (post-GAP). Using standard statistics, demographics,
resentation variables, rates of comorbidity, diagnostic tests,
reatments, and outcomes were analyzed in the two cohorts,
ncluding the use of evidence-based therapies and use of
MI standard admission and discharge tools. We examined
n-hospital, 30-day, and one-year mortality in baseline
ompared with post-GAP patients. To assess the potential
ndependent benefit of GAP on mortality, separate multi-
ariate logistic regression models for in-hospital, 30-day,
nd one-year mortality were developed. Age, troponin
evels, and heart rate were included as continuous variables.
ach hospital was included in the model as an independent
ariable to account for practice variation between facilities.
andidate variables included age (continuous), gender,
istory of MI, previous heart failure, previous chronic
bstructive pulmonary disorder, history of stroke, previous
ercutaneous coronary intervention, left ventricular ejection
raction, chest pain, hematocrit 30%, heart rate (contin-
ous), anterior MI, inferior MI, atrial fibrillation, percuta-
eous coronary intervention during the index hospitaliza-
ion, coronary artery bypass grafting during the index
ospitalization, elevated troponin (continuous), in-hospital
eart failure, hypertension, elevated creatinine, renal failure,
troke, cardiac arrest, and cardiogenic shock. To assess
hether the GAP effect was primarily driven by use of
tandardized tools, we added their use to the multivariable
odels to see whether they supplanted the apparent GAP
ffect. For in-hospital mortality, the independent effect of
sing standardized orders at admission was analyzed. To
ssess the influence of clinical care tool use on long-term
utcomes, we studied the independent effect of standardized
ischarge document on 30-day and one-year mortality, after
xcluding patients with in-hospital death.
ESULTS
mong 2,857 patients studied, 1,368 were in the baseline
ohort and 1,489 in the post-GAP cohort. Average age was
6 years. When comparing demographics, previous cardio-
ascular disease (Table 1), comorbid conditions, presenting
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ACC’s GAP Projects in Michigan October 4, 2005:1242–8ymptoms, and test results (Table 2), the two cohorts were
imilar with rare exceptions. On average, post-GAP pa-
ients a higher rate of hypertension (78.9% vs. 74.8%; p 
.01), more anterior AMIs as diagnosed by electrocardio-
ram (33.8% vs. 29.8%; p  0.02), and slightly greater
ikelihood of normal or only mildly depressed left ventric-
lar function (50.8% vs. 46.6%; p  0.03).
Table 3 lists the diagnostic and treatment approaches.
fter GAP implementation, eligible patients were more
ikely to receive aspirin in the first 24 h of admission (87.3%
able 1. Patient Characteristics
Variable
Baseline (%)
(n  1,368)
Post-GAP (%)
(n  1,489) p Value
emographics
Mean age (yrs) 76.4 76.2 0.57
Females 656 (47.9) 717 (48.1) 0.91
Non-white 211 (15.5) 245 (16.5) 0.31
mpaired functional status
Immobility 60 (6.0) 67 (5.8) 0.86
Dementia 158 (11.5) 172 (11.5) NS
Admission from care
facility
114 (8.5) 98 (6.7) 0.08
revious cardiovascular
disease
MI 572 (41.8) 675 (45.3) 0.06
CABG 270 (19.7) 294 (19.7) NS
PCI 216 (15.8) 262 (17.6) 0.19
Heart failure 482 (35.2) 533 (35.8) 0.75
Stroke 280 (20.5) 331 (22.2) 0.25
Hypertension 1,024 (74.8) 1,175 (78.9) 0.01
omorbidities
Diabetes 507 (37.1) 549 (36.9) 0.91
Current smoker 255 (18.6) 286 (19.2) 0.70
COPD 357 (26.1) 425 (28.5) 0.14
Terminal illness 1 (0.07) 1 (0.07) NS
ABG  coronary artery bypass graft surgery; COPD  chronic obstructive pulmonary
isease; MI  myocardial infarction; PCI  percutaneous coronary intervention.
Table 2. Clinical Characteristics
Variable
Bas
(n
Patient characteristics at presentation
Chest pain 97
Pain 6 h 2
Heart rate 100 beats/min 36
Heart failure 26
Electrocardiogram at presentation
LBBB 7
Atrial fibrillation 28
Paced rhythm 13
Anterior MI 40
Inferior MI 43
Test results
Creatine kinase 5  normal 22
Hematocrit 30 g/dl 15
Cardiomegaly on CXR 59
LVEF 40% (normal or mild 2) 63
LVEF 25%–39% (moderately 2) 33
LVEF 25% (severely 2) 16
LVEF not assessed 22CXR  chest X-ray; LBBB  left bundle branch block; LVEF  ls. 84.8%; p  0.05), have standardized admission orders
sed (45.5% vs. 19.8%; p  0.001), and have the discharge
ool used (30.8% vs. 1.8%; p  0.001). Among ideal
andidates, post-GAP patients were more likely to receive
spirin (90.0% vs. 81.6%, p  0.001), beta-blockers (91.6%
s. 84.2%; p  0.001), a lipid-lowering drug (78.2% vs.
3.1%; p  0.001) and an angiotensin-converting enzyme
nhibitor (81.0% vs. 77.1%; p  0.01) at discharge.
Table 4 lists in-hospital complications and mortality data.
ortality in-hospital (10.4% vs. 13.6%; p  0.017), at 30
ays (16.7% vs. 21.6%; p  0.001), and at one year (33.2%
s. 38.3%; p  0.04) was significantly lower in the post-
AP patients. Table 5 illustrates the potential independent
ffect of GAP on hospital, 30-day, and one-year mortality.
fter adjustment for clinical findings, tests, and treatments,
atients cared for post-GAP were less likely to die at 30
ays and one year, and there was a trend for better hospital
urvival as well (Table 5).
When we compared the impact of standardized care tools
ersus the overall impact of GAP, 30-day mortality was
ignificantly less likely among patients receiving the stan-
ardized discharge tool (odds ratio 0.52; 95% confidence
nterval 0.27 to 0.98; p  0.042; Table 6). This variable
esulted in elimination of the GAP effect from the model,
lthough GAP drove the use of the standard discharge tool
rom less than 2% pre-GAP to nearly 31% after GAP. Use
f the discharge tool was associated with a significant
eduction in one-year mortality (odds ratio 0.53; 95%
onfidence interval 0.36 to 0.76; p  0.0006).
ISCUSSION
revious studies have suggested that adherence to guideline-
ased therapeutic goals may have a benefit in lowering acute
nd long-term outcomes after patients suffer an AMI (17).
(%)
68)
Post-GAP (%)
(n  1,489) p Value
.3) 1,068 (73.9) 0.31
) 31 (2.5) 0.43
.6) 396 (26.7) 0.94
.8) 265 (17.8) 0.28
) 96 (7.1) 0.30
.8) 308 (20.7) 0.94
.8) 147 (11.4) 0.62
.8) 504 (33.8) 0.02
.1) 502 (33.7) 0.36
.0) 197 (17.2) 0.06
.4) 185 (12.7) 0.30
.5) 625 (49.0) 0.44
.6) 756 (50.8) 0.03
.6) 343 (23.0) 0.34
.2) 156 (10.5) 0.15
.6) 234 (15.7) 0.52eline
 1,3
0 (72
8 (2.4
1 (26
5 (17
7 (6.2
4 (20
0 (10
8 (29
9 (32
0 (20
4 (11
8 (50
8 (46
6 (24
7 (12
7 (16eft ventricular ejection fraction; MI  myocardial infarction.
B
e
r
a
i
H
i
c
u
i
n
S
t
c
n
t
s
s
d
a
g
u
i
a
q
m
h
t
w
c
e
p
a
a
c
i
c
s
a
s
t
t
i
m
c
w
d
t
ch treat
rtery b
T
C
I
L
1245JACC Vol. 46, No. 7, 2005 Eagle et al.
October 4, 2005:1242–8 ACC’s GAP Projects in Michiganecause the guidelines reflect a scientific basis for treatment
mphasizing strategies that have been studied in large
andomized clinical trials (1,3), it makes sense that the
ctual clinical use of these strategies through guideline
mplementation would lead to improved patient outcomes.
owever, most such studies have struggled to demonstrate
mprovement in process measures, let alone clinical out-
omes (18). Part of this failure has been due to only mild
ptake of guideline tools, and much has been attributable to
ssues of sample size where, unlike large clinical trials, the
umbers of patients studied have been modest (13,19).
ome reports have represented single-center initiatives over
he course of long periods of time (19) and have been
riticized as reflecting natural diffusion of knowledge into care,
ot a direct benefit of a labor-intensive guideline implemen-
ation effort. Other reports have included voluntary data entry
o that assuring similar “before and after” samples was impos-
Table 3. In-Hospital Treatment
Test or Treatment
Noninvasive tests
Echocardiogram
Gated blood pool scan
Stress test
Invasive procedures
Admission to facility with cardiac surgery capabili
Cardiac catheterization
PCI
CABG
In-hospital medical therapy*
Aspirin
Beta-blocker
Standard orders used
Discharge medical therapy*
Aspirin
Beta-blocker
Lipid-lowering agent
ACE inhibitor
Standard discharge tool used
*Data provided reflect rates of therapy among ideal patients for ea
ACE  angiotensin-converting enzyme; CABG  coronary a
able 4. Complications and Outcomes
omplications/Outcomes
Baseline (%)
(n  1,368)
Post-GAP (%)
(n  1,489)
p
Value
n hospital
Hypotension 419 (30.6) 492 (33.0) 0.17
Shock 16 (1.2) 18 (1.2) 0.92
Heart failure/pulmonary
edema
652 (47.7) 660 (44.3) 0.07
Stroke 68 (4.9) 78 (5.2) 0.74
Renal failure 340 (25.0) 357 (24.2) 0.61
Hemorrhage/bleeding 338 (24.7) 381 (25.6) 0.59
Transfusion 278 (20.3) 364 (24.4) 0.008
Discharge to acute care
hospital
174 (12.7) 162 (10.9) 0.13
In-hospital mortality 186 (13.6) 159 (10.4) 0.017
ater outcomes
30-day mortality 295 (21.6) 249 (16.7) 0.001(1-year mortality 524 (38.3) 494 (33.2) 0.004ible (20). The failure of guideline implementation efforts to
emonstrate improved outcomes has served to fuel nihilism
mong many care providers regarding the importance of
uidelines and their use in practice (21).
The ACC AMI GAP initiatives in Michigan provided a
nique opportunity to assess the effect of an active guideline
mplementation program on outcomes after AMI. We were
ble to assess the effects of GAP on not only in-hospital
uality indicators but also immediate and downstream
ortality using data gathered the preceding year as each
ospital’s control. The results suggest that across 33 hospi-
als, a rapid-cycle quality improvement effort is associated
ith a lower 30-day and one-year mortality among Medi-
are beneficiaries hospitalized for an AMI. The size of this
ffect appears to be a 21% to 26% reduction in death.
Because our study was not a randomized trial, is it really
ossible to state that GAP lowered the rate of mortality
fter an AMI in elderly patients? Although, “before and
fter” observational studies can “suggest” such effects, un-
ertainty remains. However, in the case of GAP in Mich-
gan, the accumulated evidence is consistent with this
onclusion. First, patients were selected randomly for inclu-
ion and their charts were copied and sent to a data
bstraction organization for data extraction. This procedure
hould mitigate selection bias that can cloud any observa-
ional study. Second, the degree of improvement in many of
he quality indicators after GAP correlated strongly with
ncreased use of standardized orders and discharge docu-
ents. Third, in the GAP pilot project, performance in 11
ontrol hospitals that wanted to participate in GAP but
ere not selected were compared with 10 GAP hospitals,
emonstrating that “wanting to improve” did not achieve
he degree of change observed in the participating hospitals
Baseline (%)
(n  1,368)
Post-GAP (%)
(n  1,489) p Value
846 (61.8) 893 (59.9) 0.31
57 (4.2) 98 (6.6) 0.004
112 (8.2) 163 (10.9) 0.12
768 (56.1) 902 (60.6) 0.02
618 (45.2) 713 (47.9) 0.15
261 (19.1) 344 (23.1) 0.008
110 (8.0) 138 (9.3) 0.24
873 (84.8) 896 (87.3) 0.05
509 (70.7) 520 (73.1) 0.15
271 (19.8) 677 (45.5) 0.001
694 (81.6) 819 (90.0) 0.001
247 (84.2) 285 (91.6) 0.001
364 (73.1) 510 (78.2) 0.001
327 (77.1) 331 (81.0) 0.01
21 (1.8) 409 (30.8) 0.001
ment, that is, without any contraindication (relative or absolute).
ypass graft surgery; PCI  percutaneous coronary intervention.ty10). Fourth, mortality reduction noted after GAP persisted
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ays, and 5.1% at one year. Finally, the multivariable models
or mortality appear to be robust (C-statistic  0.76) for a
ondition such as MI, and the direction and degree of the
AP effect have face validity.
Are the levels of improvement in mortality apparently
wing to the GAP effort really plausible? Could one really
xpect a 21% to 26% mortality benefit when each of the
uality indicators are only improved by an absolute amount
rom 4% to 10%? We believe the answer is yes. The GAP
rogram emphasizes more than the quality indicators re-
orted here. The system strongly endorses long-term ad-
erence to evidence-based medicines among eligible pa-
ients, encourages lifestyle interventions, and documents a
ollow-up plan at discharge. We have previously shown that
chieving multiple pharmacologic and lifestyle targets is not
n additive effect, but in fact multiplicative risk reduction in
he 6 to 12 months after an acute coronary syndrome or after
peripheral vascular intervention (22,23). Also, Fonarow et
l. (19) have shown previously a more than 50% lowering of
ne-year mortality in a study of guideline-based treatment
f AMI in an academic medical center. Finally, Lappe et al.
24) recently reported a 21% reduction in one-year mortality
fter implementing a guideline-based secondary prevention
rogram in patients hospitalized for acute cardiovascular
isorder in the mountain west states.
The discharge contract between the hospital and the
atient appears to be especially important in achieving the
ortality reduction found in this study. The discharge
ontract ensures that patients are educated about their
ondition and understand how to take care of themselves
fter they leave the hospital. It is filled out and explained to
he patient in the presence of a physician or a nurse and
ncludes instructions on taking medications, goals for con-
rolling cholesterol levels, smoking-cessation goals, diet and
xercise instructions, heart disease education, and instructions
o follow-up with the patient’s primary care physicians. Both
he patient and the provider must sign the contract.
The discharge contract forces processes to take place that
ay easily be forgotten in the busy environment of a
ospital. For the provider to explain everything on the
ontract to the patient, the provider must go through the
rocess to ensure that all the steps on the contract have been
xplained. The contract forces providers to either prescribe
spirin, beta-blockers, angiotensin-converting enzyme in-
ibitors, and cholesterol-lowering agents or document the
eason these drugs were not indicated. Similarly, the dis-
harge contract ensures that diet counseling and smoking-
essation counseling has occurred, that educational infor-
ation about heart disease and heart attacks has been
rovided to patients, and that exercise and cardiac rehabilita-
ion instructions and referrals have been given. The success of
he discharge contract lies in its ability to ensure evidence-
ased processes occur at discharge and the patient is informed
bout taking care of themselves after they leave the hospital.Why did GAP work? First, the projects were led byTa
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October 4, 2005:1242–8 ACC’s GAP Projects in Michiganhysicians and nurses, with support from the subspecialty’s
remier professional society, the ACC, and its leaders. Profes-
ional leadership and physician engagement are essential to
chieving improvement (25–27). Second, energy for change
as fueled by involvement of community stakeholders involved
ith caring for, insuring, and employing patients and their
amilies. General Motors, Ford Motor Company, Daimler-
hrysler, The United Auto Workers, Blue Cross Blue Shield
f Michigan (BCBSM), CMS, and many others supported
AP through the Greater Detroit Area Health Council and
he Greater Flint Health Coalition. Third, CMS and Michi-
an Peer Review Organization were strong collaborators for
ssistance in cardiovascular care measurement and improve-
ent in local hospitals, which was critical for the ability to
nitiate rapid cycle change. Fourth, hospitals were ready for
mprovement given the current focus of CMS, BCBSM, Joint
ommission for Accreditation of Hospital Organizations, and
thers on AMI quality. Fifth, the intervention focused on the
atient-doctor-nurse triangle of care, trying to assure that a
hort list of key care priorities was emphasized in a consistent
ay and with systems which supported these priorities during
he care itself. Sixth, assuring late benefit of treatments after
ospital discharge was enhanced through use of an AMI
ischarge form. This simple, one-page check-list guarantees
hat key pharmaceutical and lifestyle goals, their rationale, and
heir duration of use are understood both by the care provider
nd the patient. Initiation of secondary prevention treatment,
n-hospital, improves the likelihood that patient’s will be on
reatment 3 to 12 months later (28–30). Finally, the willing-
ess of physicians and nurses in Michigan to work together
eflects an appreciation that more than 40% of the state’s
itizens currently die of cardiovascular disease and that by
earning from each other, care can improve in each institution
31).
We believe that further improvement is possible. Only 32%
f the post-GAP patient charts contained a discharge contract,
nd 50% had initial care directed by standardized orders.
ne GAP hospital has moved from a culture where use of the
tandardized order sets and discharge document is “encour-
ged,” to a system where it is “guaranteed” for heart failure or
cute coronary syndromes. Patients must have orders provided
n standard sets, and use of the discharge contract is required.
atients’ charts are coded on the floor, in real time, and
eficiencies in use of standard care tools and in documentation
r adherence to quality indicators are promptly identified and
ed back to the care team and the patient. Fundamentally, this
pproach likens a missed quality of care opportunity to a
edical error. This has resulted in adherence to key quality
ndicators among eligible patients of nearly 100% (20).
tudy limitations. The cost-effectiveness of the GAP in-
ervention has not been studied. We do not know whether
AP is more or less cost-effective than other current
edical strategies. Regardless of its cost-effectiveness, ef-
orts such as GAP are being adopted because AMI quality
ndicators are now a key performance measure for hospitalaccreditation by the Joint Commission for Accreditation ofTa
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ACC’s GAP Projects in Michigan October 4, 2005:1242–8ospital Organizations, care reimbursement in Michigan by
CBSM, and will become targets of incentive-based reim-
ursement by CMS in 2005. Thus, hospitals must invest in
ertain quality initiatives to maintain excellence in care, their
ccreditation, and to maximize clinical revenues. Given these
ressures, both hospitals and caregivers are searching for
ractical methods to measure and improve performance. The
AP and the American Heart Association’s Get With the
uidelines (32) represent the most well-publicized methods to
o this for acute coronary care.
onclusions. Medicine based on memory is unreliable.
uidelines, when embedded into care systems which re-
ind patients, doctors, and nurses of care priorities, can
mprove the degree to which current medical knowledge is
irectly applied to patient care. In doing so, indirect process
easures of care improve but, more importantly, they
ranslate into improved patient outcomes. Through collabora-
ion, a systems-based approach and a professional commitment
o never-ending improvement, patients can get better care.
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